bullish
THX-ULD01 to focus on TBI
SUMMARY
Therapix reported H117 results and provided a company update in which it announced that the planned development program for sublingual ultra-low dose THC (THX-ULD01) will focus on the treatment of traumatic brain injury (TBI). The program is planned to enter a Phase I pharmacokinetic study in Q417, expected to take one month to complete. The company also reported that the Phase IIa Tourette’s study of THX-TS01 was going smoothly and eight (of 18) patients have completed the trial, seven of whom opted to remain on the drug.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Edison Investment Research
Leading International Investment Research
Price Chart(Sign Up to Access)
- THX-ULD01 to focus on TBI18 Aug 2017
x